Insulin degludec improves health-related quality of life (SF-36®) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials

@inproceedings{Freemantle2013InsulinDI,
  title={Insulin degludec improves health-related quality of life (SF-36®) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials},
  author={Nick Freemantle and Luigi F Meneghini and Torsten LU Christensen and Michael Lyng Wolden and Johan H. Jendle and Robert E. Ratner},
  booktitle={Diabetic medicine : a journal of the British Diabetic Association},
  year={2013}
}
AIM To compare the effect of insulin degludec and insulin glargine on health-related quality of life in patients with Type 2 diabetes starting on insulin therapy. METHODS Patient-level data from three open-label, randomized, treat-to-target trials of 26 or 52 weeks' duration were pooled using a weighted analysis in conjunction with a fixed-effects model. Insulin-naive patients received either insulin degludec (n = 1290) or insulin glargine (n = 632) once daily, in combination with oral anti… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 6 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 31 references

: results of a randomized pan - Asian trial

  • B Zinman, A Philis-Tsimikas, B Cariou, Y Handelsman, HW Rodbard, T Johansen
  • 2012

Insulin degludec improves glycemic control in insulin-na€ıve patients with type 2 diabetes: results of a randomized pan-Asian trial

  • Y Onishi, SW Park, SJ Yoo, P Clauson, SC Tamer, Y. Iwamoto
  • Diabetes
  • 2012

Similar Papers

Loading similar papers…